Anti-inflammatory effect of atorvastatin in patients with aortic sclerosis or mild aortic stenosis independent of hypercholesterolemia

Pharmacological Reports

Volumn 62, Issue 6, 2010, Pages 1250-1254

  Dimitrow, Pawel Petkow ^a   Jawieñ, Marek ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Outpatient Cardiologic Clinic   (Poland)

Author keywords

Aortic sclerosis; Atorvastatin; Biomarkers; Inflammation

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIACYLGLYCEROL;

ABSENCE OF SIDE EFFECTS; AGED; ANTIINFLAMMATORY ACTIVITY; AORTA ATHEROSCLEROSIS; AORTA STENOSIS; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 78649738021     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(10)70390-X     Document Type: Article

References (25)

1. Agmon Y, Khandheria BK, Jamil Tajik A, Seward JB, Sicks JD, Fought AJ, O'Fallon WM et al.: Inflammation, infection, and aortic valve sclerosis: insights from the Olmsted County (Minnesota) population. Atherosclerosis, 2004, 174, 337-342.
2. Antonini-Canterin F, Hîrşu M, Popescu BA, Leiballi E, Piazza R, Pavan D, Ginghinǎ C, Nicolosi GL: Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol, 2008, 102, 738-742.
3. Aronow WS, Ahn C, Kronzon I, Goldman ME: Association of coronary risk factors and use of statins with progression of mild valvular aortic stenosis in older persons. Am J Cardiol, 2001, 88, 693-695.
4. Bellamy MF, Pellikka PA, Klarich KW, Tajik AJ, Enriquez-Sarano M: Association of cholesterol levels, hydroxymethylglutaryl coenzyme A reductase inhibitor treatment, and progression of aortic stenosis in community. J Am Coll Cardiol, 2002, 40, 1731-1734.
5. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; for the ASTRONOMER Investigators: Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis. Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial. Circulation, 2010, 121, 306-314.
6. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA: Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med, 2005, 352, 2389-2397.
7. Dimitrow PP, Hlawaty M, Undas A, Sniezek-Maciejewska M, Sobieñ B, Stepieñ E, Tracz W: Effect of aortic valve stenosis on haemostasis is independent from vascular atherosclerotic burden. Atherosclerosis, 2009, 204, e103-e108.
8. Helske S, Otto CM: Lipid lowering in aortic stenosis: still some light at the end of the tunnel? Circulation, 2009, 119, 2653-2655.
9. Imai K, Okura H, Kume T, Yamada R, Miyamoto Y, Kawamoto T, Watanabe N et al.: C-Reactive protein predicts severity, progression, and prognosis in patients with asymptomatic AS. Am Heart J, 2008, 156, 713-718.
10. Jeevanantham V, Singh N, Izuora K, D'Souza JP, Hsi DH: Correlation of high sensitivity C-reactive protein and calcific aortic valve disease. The Mayo Clin Proc, 2007, 82, 171-174.
11. Kastellanos SS, Toumpoulis IK, Aggeli C, Zezas S, Chlapoutakis E, Kastellanos S, Stefanadis CI: Time course of C-reactive protein, tumour necrosis factor-alpha and monocyte chemoattractant protein-1 following the surgical treatment of patients with aortic valve stenosis. Hellenic J Cardiol, 2007, 48, 5-14.
12. Krysiak R, Łabuzek K, Okopieñ B: Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects. Pharmacol Rep, 2009, 61, 1134-1145.
13. Miller JD, Weiss RM, Serrano KM, Brooks RM 2nd, Berry CJ, Zimmerman K, Young SG, Heistad DD: Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation, 2009, 119, 2693-2701.
14. Mohler ER 3rd, Wang H, Medenilla E, Scott C: Effect of statin treatment on aortic valve and coronary artery calcification. J Heart Valve Dis, 2007, 16, 378-386.
15. Moura LM, Ramos SF, Zamorano JL, Barros IM, Azevedo LF, Rocha-Gonçalves F, Rajamannan NM: Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol, 2007, 49, 554-561.
16. Nagila A, Permpongpaiboon T, Tantrarongroj S, Porapakkham P, Chinwattana K, Deakin S, Porntadavity S: Effect of atorvastatin on paraoxonase1 (PON1) and oxidative status. Pharmacol Rep, 2009, 61, 892-898.
17. Nightingale AK, Horowitz JD: Aortic sclerosis: not an innocent murmur but a marker of increased cardiovascular risk. Heart, 2005, 91, 1389-1393.
18. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP: Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation, 2001, 104, 2205-2209.
19. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS: Association of aortic valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med, 1999, 341, 142-147.
20. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U, Schemper M et al.: Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation, 2004, 110, 1291-1295.
21. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerdts E et al. SEAS Investigators: Intensive lipid lowering with simwastatin and ezetimibe in aortic stenosis. N Engl J Med, 2008, 359, 1343-1356.
22. Sanchez PL, Mazzone AM: C-reactive protein in aortic valve disease. Cardiovasc Ultrasound, 2006, 4, 37.
23. Shah SJ, Ristow B, Ali S, Na BY, Schiller NB, Whooley MA: Acute myocardial infarction in patients with versus without aortic valve sclerosis and effect of statin therapy (from the Heart and Soul Study). Am J Cardiol, 2007, 99, 1128-1133.
24. Undas A, Topór-Madry R, Tracz W: Simvastatin increases clot permeability and susceptibility to lysis in patients with LDL cholesterol below 3.4 mmol/l. Pol Arch Med Wewn, 2009, 119, 354-359.
25. Yetkin E, Waltenberger J. Molecular and cellular mechanisms of aortic stenosis. Int J Cardiol, 2009, 135, 4-13.